|Videos|December 25, 2019
HER2+ mBC: DESTINY-Breast04 Trial
Author(s)Sponsored Content
The comparison of trastuzumab deruxtecan (DS-8201a) with standard chemotherapy is examined for patients with low levels of HER2 metastatic breast cancer and final thoughts on the future treatment landscape of HER2+ breast cancer.
Advertisement
The comparison of trastuzumab deruxtecan (DS-8201a) with standard chemotherapy is examined for patients with low levels of HER2 metastatic breast cancer and final thoughts on the future treatment landscape of HER2+ breast cancer.
Advertisement
Related Content
Advertisement
Advertisement
Trending on CURE
1
How to Become a Cancer Survivor and Transforming Patients into People
2
NCCN Names Trodelvy a Preferred First-Line Treatment for Metastatic TNBC
3
Immunotherapy Combo Shows Potential Progress in Some Pancreatic Cancers
4
World Cancer Day Highlights Awareness and Global Collaboration
5